What a great deal. Acadia are committed now! It’s all in on NEU! Hard to believe they’ve played this so badly in the early days. But after seeing how good Daybue is going they’ll d anything to acquire 2591.
That should get other big players to take a better look. Should guaranteed a premium for shareholders down the track a bit.
Now we need an announcement the FX Syndrome is a priority for ACAD. Whilst they have such an experienced team on the payroll. Get the trials done and FDA approval.
Now that we know how much ACAD was willing to pay for RETTS post Ph2, it won’t be hard for analysts to put a good valuation on NEU once ph2 trials are successfully completed.
If all 4 trials are successful then even $100 might look very cheap?
$13.60 is still very cheap buying. This might take a few weeks for the market ti wake up. But we are very niche, maybe we need Baker Bros to help us extract our full value here.
Neurens best announcement to date . We are chasing 6 of these indications! That’s huge. Did Jon say that 2591 was chasing a market 5 times bigger than Retts ?
NEU Price at posting:
$13.60 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)